Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: FANCD2 protects replication forks and prevents cell death in cancers deficient in BRCA1 or BRCA2 (BRCA1/2).
Figure 2: Strategy to selectively target BRCA1- or BRCA2-deficient cancers by inhibiting FANCD2 function.

References

  1. Easton, D.F. Breast Cancer Res. 1, 14–17 (1999).

    CAS  Article  Google Scholar 

  2. Michl, J., Zimmer, J., Buffa, F.M., McDermott, U. & Tarsounas, M. Nat. Struct. Mol. Biol. 23, 755–757 (2016).

    CAS  Article  Google Scholar 

  3. Kais, Z. et al. Cell Rep. 15, 2488–2499 (2016).

    CAS  Article  Google Scholar 

  4. Michl, J., Zimmer, J. & Tarsounas, M. EMBO J. 35, 909–923 (2016).

    CAS  Article  Google Scholar 

  5. Kim, H. & D'Andrea, A.D. Genes Dev. 26, 1393–1408 (2012).

    CAS  Article  Google Scholar 

  6. Lossaint, G. et al. Mol. Cell 51, 678–690 (2013).

    CAS  Article  Google Scholar 

  7. Schlacher, K., Wu, H. & Jasin, M. Cancer Cell 22, 106–116 (2012).

    CAS  Article  Google Scholar 

  8. Zhang, J. Cell Biosci. 3, 11 (2013).

    CAS  Article  Google Scholar 

  9. Schlacher, K. et al. Cell 145, 529–542 (2011).

    CAS  Article  Google Scholar 

  10. Howlett, N.G. et al. Science 297, 606–609 (2002).

    CAS  Article  Google Scholar 

  11. Sawyer, S.L. et al. Cancer Discov. 5, 135–142 (2015).

    CAS  Article  Google Scholar 

  12. Zeman, M.K. & Cimprich, K.A. Nat. Cell Biol. 16, 2–9 (2014).

    CAS  Article  Google Scholar 

  13. Mateos-Gomez, P.A. et al. Nature 518, 254–257 (2015).

    CAS  Article  Google Scholar 

  14. Ceccaldi, R. et al. Nature 518, 258–262 (2015).

    CAS  Article  Google Scholar 

  15. Boisvert, R.A. & Howlett, N.G. Cell Cycle 13, 2999–3015 (2014).

    CAS  Article  Google Scholar 

  16. Kee, Y. & D'Andrea, A.D. Genes Dev. 24, 1680–1694 (2010).

    CAS  Article  Google Scholar 

  17. Lachaud, C. et al. Science 351, 846–849 (2016).

    CAS  Article  Google Scholar 

  18. Lord, C.J., Tutt, A.N. & Ashworth, A. Annu. Rev. Med. 66, 455–470 (2015).

    CAS  Article  Google Scholar 

  19. Bouwman, P. & Jonkers, J. Clin. Cancer Res. 20, 540–547 (2014).

    CAS  Article  Google Scholar 

  20. Halazonetis, T.D., Gorgoulis, V.G. & Bartek, J. Science 319, 1352–1355 (2008).

    CAS  Article  Google Scholar 

  21. Di Micco, R., Fumagalli, M. & d'Adda di Fagagna, F. Trends Cell Biol. 17, 529–536 (2007).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Rouse.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lachaud, C., Rouse, J. A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells. Nat Struct Mol Biol 23, 701–703 (2016). https://doi.org/10.1038/nsmb.3276

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nsmb.3276

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing